TG Therapeutics (TGTX)
(Real Time Quote from BATS)
$19.99 USD
0.00 (0.00%)
Updated Aug 8, 2024 09:46 AM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TGTX 19.99 0.00(0.00%)
Will TGTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TGTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TGTX
Stock Market News for Aug 7, 2024
TG Therapeutics (TGTX) Surpasses Q2 Earnings and Revenue Estimates
TGTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates
After Plunging -9.82% in 4 Weeks, Here's Why the Trend Might Reverse for TG Therapeutics (TGTX)
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Other News for TGTX
TG Therapeutics price target raised by $5 at B. Riley, here's why
TG Therapeutics price target raised by $3 at Ladenburg, here's why
TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
Buy Rating Affirmed for TG Therapeutics on Strong Sales and Promising Pipeline Growth Prospects
Crude Oil Moves Higher; Yum! Brands Posts Upbeat Earnings